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recovery in QOL scores over time was deemed statistically 
significant (p<0.0001). A clinically and statistically significant 
improvement in physical (78.7 vs. 87.7, p=0.05), emotional 
(66.5 vs. 78.5, p=0.05) and social functioning (61.5 vs. 82.2) 
was observed in IMRT cohort. The patients treated with IMRT 
had fewer patients having symptoms of appetite loss (30.4 vs. 
12.1,p=0.01) and diarrhea (24 vs. 9;p=0.04). The use of IMRT 
was also associated with reduced lymphedema (15.2 vs 3.2; 
p=0.05). However no difference was observed in sexual and 
global QOL. 
 
Conclusion: Early results show improved functional scales 
and reduced symptom scales with use of postoperative IMRT 
when compared to 3DCRT. Further long term follow up is 
needed to clearly define the impact of IMRT on patient 
reported outcomes.  
 
PO-0731  
Quality of life of women after endometrial cancer: the role 
of the vaginal dilator 
R. Foerster
1University Hospital Heidelberg, Department of Radiation 
Oncology, Heidelberg, Germany 
1, L. Schnetzke1, T. Bruckner2, H. Rief1, J. Debus1, 
K. Lindel1 
2University Hospital Heidelberg, Department of Medical 
Biometry, Heidelberg, Germany 
 
Purpose or Objective: Pelvic radiotherapy (RT) provides 
good local control in women with endometrial cancer (EC), 
but may also cause substantial acute and chronic adverse 
effects, which in turn may reduce patients' (pts) quality of 
life (QoL). 
 
Material and Methods: 293 pts who were treated with 
adjuvant pelvic RT for EC at our department between 2004 
and 2012 were asked to fill in questionnaires regarding their 
QoL (EORTC QLQ-C30, EN24). Median follow-up was 6 years. 
112 pts agreed to participate. 42 (38%) used the vaginal 
dilator (VD; group A) as prescribed, 62 (55%) did not use the 
VD (group B), 8 (7%) preferred not to answer this question. 
The values of the function and symptom scales of the pats 
were statistically analyzed and compared between the two 
groups as well as compared with reported values of normal 
populations. 
 
Results: The values of the function and symptom scales are 
generally lower in our pts compared to an age adapted 
normal population (NP). Pts reported statistically better 
values for sexual interest and sexual activity compared to NP 
(p<.0001), while sexual enjoyment was significantly reduced 
(p<.0001). Vaginal dryness and pain during intercourse 
(p<.00001) were the leading complaints. Sexual interest and 
activity increased with age (p<.0005) in contrast to NP. Pts in 
group A were younger than in group B (p=.016). Group A 
reported significantly less pain in the back and pelvis 
(p=.005) as well as less muscular pain (p=.013). Pts using VD 
>1 year had better values for sexual interest (p=.0022) and 
sexual activity (p=.013) compared to ≤ 1 year. Pts with 
vaginal brachytherapy (IVB) only had a better global health 
status compared to pts with additional external beam RT, 
while IMRT was better than 3D-conformal RT (p<.0017). Pts 
with higher acute GI toxicity reported more chronic GI 
symptoms (p=.002) with diarrhea (p=.009), nausea/vomiting 
(p=.032) as well as poorer social functioning (p=.036). Pts 
with higher acute GU toxicity reported more pain during 
intercourse (p=.044). 
 
Conclusion: Pelvic RT substantially affects QoL even years 
after treatment. Women participating in our study were more 
sexually active than the normal population. Therefore 
sexuality is important for QoL in women after endometrial 
cancer, even at higher age. The vaginal dilator is capable of 
improving chronic pelvic pain, sexual interest and sexual 
activity when used longer than one year. Pts with higher 
acute toxicities also exhibit more chronic problems. IMRT 
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Purpose or Objective: Uterine motion is a challenging issue 
in applying intensity-modulated radiotherapy (IMRT) for 
patients with cervical cancer. In this study we quantified the 
inter-fraction uterus movement during a course of definitive 
radiotherapy (RT) to determine the predictive factors 
affecting uterine motion. 
 
Material and Methods: A total of 343 cone-beam CT 
(CBCT）scans from 43 patients who underwent definitive RT 
were analyzed retrospectively. The median age of the 
patients was 58 years (range, 34-85 years). The FIGO stages 
were as follows: IB1, 9; IB2, 6; IIA, 1; IIB, 12; IIIB, 10; and 
IVA, 5. Cervical and corpus movement (mm) were measured 
for each direction (cranial [C), anterior [A), left [L) and right 
[R) for the uterine corpus; and A, posterior [P), L, and R for 
the cervix） by comparing planning CT and CBCT. The mean 
movement of each patient was analyzed according to the 
following factors: age; tumor stage; BMI; area of visceral fat 
in the umbilical plane, as assessed by CT; circumference of 
abdominal girth; history of abdominal surgery; uterine 
orientation (anteverted or retroverted); size of the uterus; 
tumor diameter; and tumor invasion to the corpus． 
 
Results: The mean movement of the corpus was as follows: 
C, 5.8 mm (range, 0-29.0 mm); A, 5.2 mm (range, 0.3-37.7 
mm); L, 2.4 mm (range, 0-10.6 mm); and R, 2.5 mm (range, 
0-9.2 mm). The mean movement of the cervix was as follows: 
A, 3.2 mm (range, 0-11.4 mm); P, 2.4 mm (range, 0-12.5 
mm); L, 1.5 mm (range, 0-9.2 mm); and R, 1.6 mm (range, 0-
7.3 mm). There was a significant correlation between 
abdominal girth and anterior movement of the corpus (r=-3.6 
and p=0.029). Tumor invasion to the corpus had a negative 
correlation with posterior movement of the cervix with 
marginal statistical significance (p=0.05)． 
 
Conclusion: The study demonstrated that abdominal girth 
and tumor invasion to the corpus were predictive factors of 
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Purpose or Objective: The aim of this study is to investigate 
the ADCmean of the primary tumor to evaluate their 
correlations with the recurrence and survival rates in patients 
with primary cervical cancer before and after definitive CRT. 
 
Material and Methods: The data of 44 patients with 
histologically proven squamous cell carcinoma of cervix was 
retrospectively evaluated .All patients had multi-parametric 
pelvic MR imaging (CE-MRI and DW-MRI) and 18F-FDG PET/CT 
for initial staging prior to treatment and also multi-
parametric pelvic MR imaging after treatment at our 
Institution between February 2009 and May 2014. ADC 
response was measured by the proportion of ADC changes 
between pretreatment and posttreatment ADC measured in 
DW-MRI. The patients were divided into groups based on the 
pretreatment and posttreatment ADCmean of the primary 
tumor cutoff values derived from the ROC curves. Disease-
